Aalborg University

The General Hospital Corporation

The Ohio State University

Beth Israel Deaconess Medical Center, Inc.

Andreas Petri

Sakari Kauppinen

Anders M Naar

Daniel Arie Haber

Shyamala Maheswaran

David T Ting

Francesca Bersani

Mihir Shivadatta Rajurkar

Pier Paolo Pandolfi

Robert J Lee

Ramiro Garzon

Riccardo Panella

Adrienne M Dorrance

Dimitrios Papaioannou

Charlotte AlbÆk Thrue

Methods for treating cancer, e.g., cancer of epithelial origin, by specifically targeting human satellite II (HSATII) using sequence specific agents such as oligonucleotides.

Targeting human satellite II (HSATII)

The present disclosure provides compositions and methods that inhibit the activity of microRNAs, for example miR-22.

Inhibitors of micro-RNA 22

Methods of treating Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), comprising administering an inhibitory nucleic acid that targets miR-128.

Therapeutic targeting of a microRNA to treat Duchenne muscular dystrophy

The present disclosure relates to antisense oligomers targeting the long non-coding RNA HOXB-AS3 and methods of treating acute myeloid leukemia.

Antisense oligomers targeting HOXB-AS3 long non-coding RNA

Methods for treating cancer, e.g., cancer of epithelial origin, by specifically targeting human satellite II (HSATII) using sequence specific agents such as oligonucleotides. As shown herein, the hetero chromatic HSATII satellite repeat is silenced in normal cells, but massively over expressed in epithelial cancers and in cancer cell lines when grown as xenografts or in 3D culture. Induction of HSATII RNA, either in xenografts or using in vitro reconstitution models, suggests the appearance of complementary DNA intermediates.

Growing community of inventors

Frederiksberg, Denmark

Andreas Petri